MedTrace Logo

Absolute Bioavailability of Reslizumab in Healthy Subjects

NCT01990443 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2014-03-31

No results posted yet for this study

Summary

The primary objective of this study is to assess the absolute bioavailability of reslizumab following administration of a single subcutaneous (sc) dose to healthy non-Japanese participants

Conditions

  • Absolute Bioavailability

Interventions

DRUG

Reslizumab IV

Reslizumab 220-mg intravenous (IV)

DRUG

Reslizumab SC

Reslizumab 220 mg administered subcutaneous (SC)

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2013-12-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01990443 on ClinicalTrials.gov